Generic Drugs Forum (GDF) 2026 - 04/22/2026

Why It Matters

The forum accelerates generic drug approvals, helping lower drug costs and improve patient access while providing essential CE credits for regulatory professionals.

Key Takeaways

• FDA offers live guidance on pre-ANDA and ANDA processes
• Event provides up to 12 CE credits for RAPS recertification
• Virtual attendance via Adobe Connect expands global participation
• Focus on quality, manufacturing, and controlled correspondence topics
• Resources include GDUFA guidances, MAPP policies, and webinars

Pulse Analysis

The generic drug market accounts for roughly 80% of all prescriptions in the United States, yet developers often grapple with complex regulatory pathways that can delay market entry. By convening FDA subject‑matter experts in one forum, the Generic Drugs Forum creates a rare opportunity for manufacturers to clarify pre‑ANDA expectations, align on ANDA assessment criteria, and address quality‑manufacturing challenges before filing. This proactive engagement reduces iterative cycles, shortens review timelines, and ultimately brings lower‑cost alternatives to patients faster.

Beyond regulatory insight, the event’s continuing‑education component adds tangible value for professionals seeking to maintain certifications. Up to 12 RAPS credits, along with recognitions from SOCRA, SQA, and ACRP, incentivize attendance and reinforce best‑practice standards across the industry. The hybrid format—combining on‑site sessions with Adobe Connect streaming—broadens reach, allowing international stakeholders to participate without travel barriers, while still meeting the real‑time attendance requirement for CE eligibility.

Looking ahead, the forum’s emphasis on resources such as GDUFA guidances, the Manual of Policies & Procedures, and archived webinars equips companies with a living toolkit for compliance. As the FDA continues to refine user‑fee structures and quality expectations, participants leave with actionable roadmaps that can translate into smoother submissions and faster approvals. In a climate where drug pricing scrutiny intensifies, accelerating generic entry not only benefits consumers but also strengthens the competitive landscape for manufacturers.